Drugs News and Research

RSS

New article shows taxonomic classification of rare genetic bone disorders based on metabolic phenotypes

An International Osteoporosis Foundation Working Group on Skeletal Rare Diseases has published a new classification of rare genetic metabolic bone disorders (RGMBDs) according to their metabolic pathogenesis.

18 Jun 2015

University of Michigan, AstraZeneca team up to identify novel targets for chronic kidney disease

AstraZeneca today announced a two-year research collaboration with the University of Michigan to advance the treatment of chronic kidney disease (CKD) through the improved understanding of the disease. The collaboration will tackle the challenging area of identifying novel targets for the treatment of CKD, focusing on the use ofpatient tissue and validation of preclinical models.

18 Jun 2015

New technique could allow scientists to pinpoint areas on enzymes that drive chemical reactions

Researchers from Cardiff University have pioneered a new technique that will enable scientists to precisely pinpoint the areas on an enzyme that help to speed up chemical reactions.

18 Jun 2015

Australian researchers discover gene involved in muscular dystrophy

Australian researchers have made a critical discovery about a gene involved in muscular dystrophy that could lead to future therapies for the currently untreatable disease.

18 Jun 2015

CGRP monoclonal antibodies show promise in treating migraine

Migraine researchers and clinicians are growing excited about a new class of drugs called Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies, which are showing promise in treating high-frequency episodic migraine and chronic migraine.

17 Jun 2015

RPCI receives NCI grant to continue research program on photodynamic therapy for head and neck cancers

Roswell Park Cancer Institute has received continuation of a prestigious program project grant from the National Cancer Institute for research through the Roswell Park Photodynamic Therapy Center.

17 Jun 2015

MGH-CEM researchers develop novel approach to evaluate the liver's drug-metabolizing activity

A team of researchers from the Massachusetts General Hospital Center for Engineering in Medicine (MGH-CEM) has developed a novel approach that dramatically simplifies the evaluation of the liver's drug-metabolizing activity and the potential toxic effects of the products of that activity on other organs.

17 Jun 2015

TSRI chemists invent scalable method for synthesizing brain-protecting compound

Chemists at The Scripps Research Institute have invented the first practical, scalable method for synthesizing jiadifenolide, a plant-derived molecule that may have powerful brain-protecting properties.

17 Jun 2015

TSRI study confirms role of Rhes protein in Huntington's disease

Huntington's disease attacks the part of the brain that controls movement, destroying nerves with a barrage of toxicity, yet leaves other parts relatively unscathed.

17 Jun 2015

Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases

The Johns Hopkins University and Bayer HealthCare have entered into a five-year collaboration agreement to jointly develop new ophthalmic therapies targeting retinal diseases. The goal of the strategic research alliance is to accelerate the translation of innovative approaches from the laboratory to the clinic, ultimately offering patients new treatment options for several retinal diseases.

17 Jun 2015

Medicare prescription drug benefit did not save any money overall, say researchers

For years, the Medicare prescription drug benefit Part D has been credited with positively impacting national trends in health outcomes and medical services. But a recent study led by Northeastern associate professor Becky Briesacher challenges that assumption and suggests that the U.S. Congressional Budget Office's adopted a new costing method based on assumed cost-savings may be "premature."

17 Jun 2015

CytomX closes $70 million Series D financing round

CytomX, a biotechnology company developing Probody™ therapeutics for the treatment of cancer, today announced the closing of a $70 million Series D financing round. The financing was led by Fidelity Management & Research Company with participation from Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Healthcare Investors and Tekla Life Sciences Investors, Venrock Healthcare Capital Partners, Wellington Management Company and additional undisclosed investors.

17 Jun 2015

CQDM, OCE grant $1.5M to speed up drug discovery and development in Quebec-Ontario Life Sciences Corridor

CQDM and Ontario Centres of Excellence will fund five highly innovative and unconventional game-changing research and development projects to accelerate drug discovery in the Quebec-Ontario Life Sciences Corridor. Partners are granting $1.5M to Quebec-based and, for the first time, Ontario-based researchers thanks to the partnership with OCE through CQDM's 2014 Explore Program, one of CQDM's flagship programs focusing on early concept validation of cutting-edge technologies that address the most crucial needs in drug discovery and development.

17 Jun 2015

Scientists identify two new key players involved in development of prostate cancer

Understanding how a normal healthy cell turns into a cancerous one is our best bet yet for beating the disease. It will help better diagnose the cancer type, and enable the development of more effective, and less toxic therapies. But cells have evolved all sorts of sophisticated ways to become cancerous, and identifying the molecules involved and how they function in each type of cancer is a major undertaking.

16 Jun 2015

Key prostaglandin metabolic enzyme shows promise as drug target for tissue regeneration

A new study co-led by Hsin-Hsiung Tai, professor of pharmaceutical sciences at the University of Kentucky, suggests that a key prostaglandin (PG) metabolic enzyme shows promise as a drug target to help tissue regeneration and repair, particularly after bone marrow transplantation and tissue injuries.

16 Jun 2015

PNP Therapeutics granted FDA orphan drug designation for Gedeptin

PNP Therapeutics Inc. announced today the Food and Drug Administration has granted orphan drug status to Gedeptin, the Company's lead product candidate (adenoviral vector expressing E. coli purine nucleoside phosphorylase gene) for the intratumoral treatment of anatomically accessible oral and pharyngeal cancers, including cancers of the lip, tongue, gum, floor of mouth, salivary gland and other oral cavities.

16 Jun 2015

FDA grants Fast Track designation to Juventas' JVS-100 drug candidate and allows Phase 2b clinical trial

Juventas Therapeutics, Inc., a clinical-stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body, today announced that its product candidate, JVS-100, received Fast Track designation from the U.S. Food and Drug Administration for the treatment of advanced ischemic chronic heart failure.

16 Jun 2015

Apexigen initiates APX005M Phase 1 clinical trial in adults with solid tumors

Apexigen, Inc., a biopharmaceutical company discovering and developing innovative antibody drugs for the treatment of cancer and other life-threatening diseases, announced today the initiation of a Phase 1 clinical trial of APX005M, the company's lead proprietary anticancer program.

16 Jun 2015

Althea obtains European GMP certificate from HPRA for commercial aseptic filling and testing

Ajinomoto Althea, Inc., a leading provider of biopharmaceutical contract development and manufacturing services announced today that it has officially received its European GMP certificate from the Health Products Regulatory Authority for commercial aseptic filling and testing.

16 Jun 2015

West Pharmaceutical Services hosts groundbreaking ceremony for new manufacturing facility in Ireland

West Pharmaceutical Services, Inc., a global leader in innovative packaging components and drug delivery systems, hosted a groundbreaking ceremony in Waterford, Ireland today to mark the start of construction for the company's new pharmaceutical component manufacturing facility. Attended by Cllr James Tobin, Mayor of Waterford City and County; Cllr Lola O'Sullivan, Mayor of Waterford Metropolitan District; and other local officials, the event celebrated West's continued investment in Ireland and commitment to the local Waterford community.

16 Jun 2015

Drugs News and Research

New article shows taxonomic classification of rare genetic bone disorders based on metabolic phenotypes

University of Michigan, AstraZeneca team up to identify novel targets for chronic kidney disease

New technique could allow scientists to pinpoint areas on enzymes that drive chemical reactions

Australian researchers discover gene involved in muscular dystrophy

CGRP monoclonal antibodies show promise in treating migraine

RPCI receives NCI grant to continue research program on photodynamic therapy for head and neck cancers

MGH-CEM researchers develop novel approach to evaluate the liver's drug-metabolizing activity

TSRI chemists invent scalable method for synthesizing brain-protecting compound

TSRI study confirms role of Rhes protein in Huntington's disease

Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases

Medicare prescription drug benefit did not save any money overall, say researchers

CytomX closes $70 million Series D financing round

CQDM, OCE grant $1.5M to speed up drug discovery and development in Quebec-Ontario Life Sciences Corridor

Scientists identify two new key players involved in development of prostate cancer

Key prostaglandin metabolic enzyme shows promise as drug target for tissue regeneration

PNP Therapeutics granted FDA orphan drug designation for Gedeptin

FDA grants Fast Track designation to Juventas' JVS-100 drug candidate and allows Phase 2b clinical trial

Apexigen initiates APX005M Phase 1 clinical trial in adults with solid tumors

Althea obtains European GMP certificate from HPRA for commercial aseptic filling and testing

West Pharmaceutical Services hosts groundbreaking ceremony for new manufacturing facility in Ireland

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News